REPL Replimune Group Inc
Price (delayed)
$8.62
Market cap
$663.87M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.07
Enterprise value
$565.96M
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary
Highlights
The company's equity rose by 26% QoQ and by 14% YoY
The company's EPS rose by 2.8% YoY
Replimune Group's quick ratio has increased by 13% from the previous quarter but it has decreased by 8% YoY
The net income has contracted by 9% YoY and by 7% from the previous quarter
Key stats
What are the main financial stats of REPL
Market
Valuations
Earnings
Shares outstanding
77.01M
Market cap
$663.87M
Enterprise value
$565.96M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.22
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$241.06M
Net income
-$228.24M
EBIT
-$219.87M
EBITDA
-$216.52M
Free cash flow
-$191.98M
Per share
Balance sheet
Liquidity
EPS
-$3.07
EPS diluted
-$3.07
Free cash flow per share
-$2.3
Book value per share
$7.05
Revenue per share
$0
TBVPS
$7.23
Total assets
$603.63M
Total liabilities
$121.25M
Debt
$76.04M
Equity
$482.37M
Working capital
$499.69M
Debt to equity
0.16
Current ratio
11.43
Quick ratio
11.3
Net debt/EBITDA
0.45
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-43%
Return on equity
-54.8%
Return on invested capital
-50.5%
Return on capital employed
-39.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
REPL stock price
How has the Replimune Group stock price performed over time
Intraday
2.62%
1 week
-17.12%
1 month
-32.02%
1 year
20.9%
YTD
-28.82%
QTD
-11.59%
Financial performance
How have Replimune Group's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$241.06M
Net income
-$228.24M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 9% YoY and by 7% from the previous quarter
The operating income has declined by 5% year-on-year and by 4.1% since the previous quarter
Growth
What is Replimune Group's growth rate over time
Valuation
What is Replimune Group stock price valuation
P/E
N/A
P/B
1.22
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 2.8% YoY
REPL's price to book (P/B) is 50% lower than its 5-year quarterly average of 2.4 and 26% lower than its last 4 quarters average of 1.6
The company's equity rose by 26% QoQ and by 14% YoY
Efficiency
How efficient is Replimune Group business performance
REPL's ROE is down by 28% YoY and by 3.2% QoQ
Replimune Group's return on invested capital has decreased by 26% YoY and by 8% QoQ
Replimune Group's return on assets has decreased by 20% YoY and by 3.6% QoQ
Dividends
What is REPL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for REPL.
Financial health
How did Replimune Group financials performed over time
The total assets is up by 21% from the previous quarter and by 13% YoY
Replimune Group's quick ratio has increased by 13% from the previous quarter but it has decreased by 8% YoY
Replimune Group's debt is 84% less than its equity
The company's equity rose by 26% QoQ and by 14% YoY
The debt to equity has declined by 20% since the previous quarter and by 11% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.